Early Drug Development Summit 2012

The Early Drug Development Summit brings early drug developers together to discuss maximising drug investments, toxicology, safety and biomarkers. The summit addresses the strategies and tools to fully optimise the drug development trajectory in order to bring safe, effective and commercially viable drugs to market faster whilst achieving regulatory approval.

Hear about the smart deployment of drug development processes and platform technologies to help maximise new product value and increase the likelihood of new drugs being approved by regulators quickly.

Benefits

The Early Drug Development Summit 2012 is the must attend event for all those looking to optimise early development processes. Attendees will discuss the strategies and tools to fully optimise the drug development trajectory in order to bring safe, effective and commercially viable drugs to market faster and achieving regulatory approval.

This year’s summit will feature case studies and interactive sessions lead by the world’s leading drug development professionals in early, toxicology and biomarker specialist companies to help you gain the most out of attending.

Benefits include:

-Stream sessions with in-depth presentations providing you with the choice to tailor the event to your needs

-Case studies from experts detailing practical advice and best practice for all pharmaceutical drug developmental experts

-Pre-scheduled one-to-one meetings, maximising your networking opportunities with selected solution providers

-Discussion tables, including lively debate and interaction with industry peers

-Workshops, with interactive participation, specialist advice, and Q&A sessions

keynote Speakers

Dr Andy Parsons,Frederik Deroose,Ian Wilson,Lucette Doessegger and many more.